Roy Smythe - Sep 1, 2021 Form 3 Insider Report for SomaLogic, Inc. (SLGC)

Role: Chief Executive Officer, Director
Signature: /s/ Ruben Gutierrez, Attorney-in-Fact
Stock symbol: SLGC
Transactions as of: Sep 1, 2021
Transactions value $: $0
Form type: 3
Date filed: 9/10/2021, 07:09 PM
Next filing: Dec 13, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	SLGC	Employee Stock Option (Right to Buy)	Sep 1, 2021	Class A Common Stock, par value $0.0001	385K	$4.77	Direct	F1, F2
holding	SLGC	Employee Stock Option (Right to Buy)	Sep 1, 2021	Class A Common Stock, par value $0.0001	1.68M	$4.77	Direct	F1, F2
holding	SLGC	Employee Stock Option (Right to Buy)	Sep 1, 2021	Class A Common Stock, par value $0.0001	1.01M	$4.77	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F2	In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II, Inc. or "CMLS") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of SomaLogic Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock (the "Exchange Ratio"). In addition, each outstanding SomaLogic equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the SomaLogic equity awards.

Content

25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences II, Inc. or "CMLS") and SomaLogic, Inc. ("SomaLogic"), among other things, each share of SomaLogic Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock (the "Exchange Ratio"). In addition, each outstanding SomaLogic equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the SomaLogic equity awards.